Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Molecular and Clinical Oncology|March 21, 2014
Clinical presentation of anaplastic large-cell lymphoma in the central nervous systemMasashi Nomura, Yoshitaka Narita, Yasuji Miyakita, et al.
Brain Tumor Pathology|August 23, 2014
Multinodular and vacuolating neuronal tumor of the cerebrumShintaro Fukushima, Akihiko Yoshida, Yoshitaka Narita, et al.
Clinical Neurology and Neurosurgery|March 27, 2012
Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed?Yoshiko Okita, Yoshitaka Narita, Yasuji Miyakita, et al.
Journal of Personality and Social Psychology|November 2, 2018
Farming cultivates a community-level shared culture through collective activities: Examining contextual effects with multilevel analysesYukiko Uchida, Kosuke Takemura, Shintaro Fukushima, et al.
Brain Tumor Pathology|March 19, 2013
Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiationShintaro Fukushima, Akihiko Yoshida, Kazufumi Honda, et al.
Brain Tumor Pathology|October 22, 2013
Short communication: sclerosing meningioma in the deep sylvian fissureShintaro Fukushima, Yoshitaka Narita, Motoki Yonezawa, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|February 15, 2013
A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapyShintaro Fukushima, Yoshitaka Narita, Yasuji Miyakita, et al.
Brain Tumor Pathology|April 22, 2014
Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomasHideyuki Arita, Yoshitaka Narita, Yuko Matsushita, et al.
Brain Tumor Pathology|July 14, 2012
Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation statusMakoto Ohno, Yoshitaka Narita, Yasuji Miyakita, et al.
International Journal of Oncology|July 25, 2012
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapyYoshiko Okita, Yoshitaka Narita, Yasuji Miyakita, et al.
Pageof 5